ProstatitisNCT07324239
TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
A study testing TECAR therapy in people with Prostatitis, run by Middle East University at 1 site in Egypt.
Trial summary
Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome. Read more about this study
- Who is it for?
- Ages 30 to 50 years, men only
- Conditions the study is for
- Prostatitis
- What is being tested?
- TECAR therapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 2 Jan 2026to 7 Apr 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 50 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- Presence of chronic prostatitis/chronic pelvic pain symptoms for more than 6 months.
- Ages will be ranged from 30 to 50 years old.
Who cannot join
- Urinary and seminal infections.
- Recent parenteral steroid administration.
- Prior prostate or pelvic surgery.
- Lower urinary tract disorders such as bladder stones.
- Implanted electronic devices as pacemakers.
- Sensory loss over the perineum.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Mohammed Elhamrawy, Ph.D contact
Egypt1 site
Tanta University Hospital
Tanta
Mohamed Rady Ewis, mohamedrady@yahoo.com
About this study
Official title: Effect of TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Randomized Controlled Trial
Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome.
Read the detailed description
Sixty men with chronic prostatitis/chronic pelvic pain will be sourced from the urology outpatient clinic at Tanta University hospitals in Egypt, with referrals from urologists. Patients will be randomly assigned into two groups.
Study group: It will include 30 men receiving true TECAR therapy plus dietary and life style adjustments.
Control group: It will include 30 men receiving sham TECAR therapy plus dietary and life style adjustments.
Evaluation Procedures:
- Pain, voiding, and quality of life using the National Institutes of Health-Chronic Prostatitis Symptom Index.
- Sleep quality using the Pittsburgh Sleep Quality Index.
- Erectile function using the International Index of Erectile Function.
- Conditions
- Prostatitis
- Being tested
- TECAR therapy, Sham TECAR therapy
- Medical subject headings
- Prostatitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TECAR therapyDevice
WINBACK 3SE (France) will be used for TECAR therapy in this study. To facilitate optimal distribution of endogenous heat therapy and effective contact between the active electrodes, both capacitive and resistive, and the surface of the skin, a layer of high-conductivity cream will be applied to the treatment region. The plate, an inactive electrode, which has a specific size (21cm*15cm), will be placed on the gluteal region. The capacitive electrode was employed for a duration of seven and a half minutes, at an intensity of 30-40%, whereas the resistance electrode will be utilized for an equivalent period over the perineum at the same intensity.
Sham TECAR therapyDevice
The procedure is similar to the active treatment of TECAR, but with the critical difference being that the output intensity of the TECAR device will be set to zero during the session.
| Study group | Role | What they receive |
|---|---|---|
| TECAR therapy group | Active comparator | Not described Receives: Device: TECAR therapy |
| Control group | Sham comparator | Not described Receives: Device: Sham TECAR therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pelvic pain
Pain will be assessed using the National Institutes of Health-Chronic Prostatitis Symptom Index
Measured: Baseline and 8 weeks later
Secondary outcomes (1)
Quality of life of men
Quality of life will be assessed using the National Institutes of Health-Chronic Prostatitis Symptom Index
Measured: Baseline and after 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2026
- Study start2 Jan 2026 (estimated)
- Primary completion1 Apr 2026 (estimated)
- Study completion7 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ProstatitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Middle East University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Saher Lotfy El Gayar, Middle East University
- Investigators
- Mohammed Saif, Study director, National institute for Gerontology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07324239
- Sponsor's protocol ID
- TECAR therapy
- Status last verified
- Dec 2025
- First submitted
- 23 Dec 2025
- Last updated
- 7 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07324239
- Acronym / sponsor ID
- TECAR therapy
- Conditions
- Prostatitis
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Middle East UniversityUniversity, hospital or other
- Study start
- 2 Jan 2026 (estimated)
- Primary completion
- 1 Apr 2026 (estimated)
- Study completion
- 7 Apr 2026 (estimated)
- First posted
- 7 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluate the effect of TECAR therapy on pain, voiding, erectile function, sleep quality and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome.
Detailed description
Sixty men with chronic prostatitis/chronic pelvic pain will be sourced from the urology outpatient clinic at Tanta University hospitals in Egypt, with referrals from urologists. Patients will be randomly assigned into two groups.
Study group: It will include 30 men receiving true TECAR therapy plus dietary and life style adjustments.
Control group: It will include 30 men receiving sham TECAR therapy plus dietary and life style adjustments.
Evaluation Procedures:
- Pain, voiding, and quality of life using the National Institutes of Health-Chronic Prostatitis Symptom Index.
- Sleep quality using the Pittsburgh Sleep Quality Index.
- Erectile function using the International Index of Erectile Function.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| TECAR therapy group | Active comparator | Device: TECAR therapy |
| Control group | Sham comparator | Device: Sham TECAR therapy |
Who may qualify
- Ages
- 30 to 50 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Presence of chronic prostatitis/chronic pelvic pain symptoms for more than 6 months.
- Ages will be ranged from 30 to 50 years old.
Key exclusion criteria (6 listed)
- Urinary and seminal infections.
- Recent parenteral steroid administration.
- Prior prostate or pelvic surgery.
- Lower urinary tract disorders such as bladder stones.
- Implanted electronic devices as pacemakers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TECAR therapyWINBACK 3SE (France) will be used for TECAR therapy in this study. To facilitate optimal distribution of endogenous heat therapy and effective contact between the active electrodes, both capacitive and resistive, and the surface of the skin, a layer of high-conductivity cream will be applied to the treatment region. The plate, an inactive electrode, which has a specific size (21cm*15cm), will be placed on the gluteal region. The capacitive electrode was employed for a duration of seven and a half minutes, at an intensity of 30-40%, whereas the resistance electrode will be utilized for an equivalent period over the perineum at the same intensity. | Device | TECAR therapy group |
| Sham TECAR therapyThe procedure is similar to the active treatment of TECAR, but with the critical difference being that the output intensity of the TECAR device will be set to zero during the session. | Device | Control group |
Primary outcome
Pelvic pain
Time frame: Baseline and 8 weeks later
Pain will be assessed using the National Institutes of Health-Chronic Prostatitis Symptom Index
1 secondary outcome
Quality of life of men
Time frame: Baseline and after 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Prostatitis
Recruiting
EPPIC: Easing Pelvic Pain Interventions Clinical Research Program
Urologic Chronic Pelvic Pain Syndrome (UCPPS), Interstitial Cystitis
Enrolling by invitation
Pulsed Electromagnetic Versus Hydrotherapy on Chronic Pelvic Pain
Chronic Pelvic Pain Syndrome
Recruiting
Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain
Erectile Dysfunction Due to Arterial Insufficiency, Erectile Dysfunction
Not yet recruitingPhase 3
FOsfomycin for Male Urinary Tract Infection
Urinary Tract Infection, Prostatitis
RecruitingObservational study
Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Chronic Prostatitis (CP), Chronic Pelvic Pain Syndrome (CPPS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mohammed Elhamrawy, Ph.D contact
Mohammed Saif study director
National institute for Gerontology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing TECAR therapy in people with Prostatitis, run by Middle East University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Saher Elgayar, Ph.D (+201020429911, saherlotfy020@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pelvic pain (time frame: Baseline and 8 weeks later). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.